SecBot SecBot

CADL

Candel Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001841387 Biotech & Drug Discovery
$7.84 −0.19 (−2.37%)
Oct 26 4:00 PM ET · prev $8.03
Market cap
$641.2M
Small cap
Consensus
Buy
93% Buy or better · 15 analysts
Median target
$23.00
+193% · range $15.00–29.00
Next earnings
Nov 5
in 10 days · EPS est. −$0.31
1 year
+45.2%
from $5.40 · Oct 27
30 days
−29.9%
from $11.19
52-week range
$4.42–13.75
−43% from high · low Nov 19
Avg volume 20D
981.3K
shares / day
Short interest
13.00M
≈17.0% of shares · +5.3%
Days to cover
11.2
at average volume
Insider net
−$550.7K
1 buyer · 3 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 8 reports · 90 days
Balance 0 bearish · 2 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 6/8 ·Next Earnings date, Nov 5, 2026
Strongest BULLISH Candel Therapeutics announced peer-reviewed publication of final Phase 2a data for aglatimagene besadenovec…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersMIXED

    1 insider bought $3.0M at an average $5.45. 3 insiders sold $3.6M. Price is 44% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 35 added (0 new), 6 trimmed or exited.

  • AnalystsBULLISH

    14 of 15 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +5.3% to 13.00M shares. 11.2 days to cover, ≈17.0% of shares.

  • TrendDOWNTREND

    29% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD4,969,040$51.2M
STATE STREET CORPDOUBLED3,549,823$36.6M
GEODE CAPITAL MANAGEMENT, LLCADD1,571,021$16.2M
NORTHERN TRUST CORPADD492,465$5.1M
VANGUARD PORTFOLIO MANAGEMENT LLCADD437,150$4.5M
VANGUARD FIDUCIARY TRUST COADD412,109$4.2M
GOLDMAN SACHS GROUP INCADD305,216$3.1M
BANK OF AMERICA CORP /DE/DOUBLED278,944$2.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 93% rate it Buy or better
Strong Buy5Buy9Hold1Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +193%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 22, 2026Jefferies
INITIATE
INITIATEBuy
Sep 21, 2026B of A Securities
UPGRADE
UPGRADEBuy
Aug 14, 2026B of A Securities
MAINTAIN
MAINTAINNeutral
Aug 13, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jul 13, 2026Stifel
INITIATE
INITIATEBuy

Insider ledger

Form 4
$3.0M
bought · 1 insider
$3.6M
sold · 3 insiders
+43.9%
vs their $5.45 cost
DateInsiderTypeValue
Sep 30, 2026
Manning Paul B
Director
AWARD$19.0K
Sep 30, 2026
Loggia Nicoletta
Director
AWARD$3.3K
Sep 30, 2026
PAPA JOSEPH C
Director
AWARD$11.5K
Sep 11, 2026
Tak Paul Peter
Chief Executive Officer
SELL$620.9K
Sep 10, 2026
Tak Paul Peter
Chief Executive Officer
EXERCISE$193.8K
Sep 10, 2026
Tak Paul Peter
Chief Executive Officer
SELL$2.5M
Sep 8, 2026
Zimmermann Martine
Director
AWARD64,000 sh
Aug 17, 2026
Tyagarajan Seshu
Chief Technology Officer
SELL$84.0K

Earnings setup

Estimates
Nov 5
reports in 10 days
−$0.31
EPS estimate, this quarter
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.31-$0.33–-$0.29-24.0%$0.00
Next Q-$0.33-$0.33–-$0.32-6.6%$0.00
Current FY-$1.08-$1.28–-$0.74-7.7%$0.00
Next FY-$0.63-$1.47–$0.22+0.0%$41.9M

Short side

FINRA· Sep 30, 2026
13,000,504
shares short
+5.3%
vs prior settlement
11.2
days to cover
≈17.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 Other
Candel Therapeutics Appoints Maria Ostrovsky as General Counsel
Seasoned legal and compliance executive brings global product launch, strategic transaction and inte
Oct 1, 2026 Press
Candel Therapeutics announced peer-reviewed publication of final Phase 2a data for aglatimagene besadenovec plus…
Impact 7/10
Sep 30, 2026 Press
Candel Therapeutics presented new biomarker data at ASTRO 2026 showing its lead candidate aglatimagene significantly…
Impact 4/10
Sep 30, 2026 Insider
Manning Paul B was granted 2,189 shares
Director @ $8.68 ($19.0K)
Sep 30, 2026 Insider
Loggia Nicoletta was granted 380 shares
Director @ $8.68 ($3.3K)
Sep 30, 2026 Insider
PAPA JOSEPH C was granted 1,325 shares
Director @ $8.68 ($11.5K)
Sep 10, 2026 SEC
Candel Therapeutics appointed Martine Zimmermann, PharmD, to its Board of Directors, effective September 8, 2026…
8-K — Impact 4/10
Sep 9, 2026 SEC
Candel Therapeutics filed an 8-K furnishing a September 2026 corporate investor presentation. The presentation…
8-K — Impact 4/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
CADL Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Oct 22, 2026
Press release
Candel Therapeutics Appoints Maria Ostrovsky as General Counsel
Seasoned legal and compliance executive brings global product launch, strategic transaction and international operational experience as Candel…
Oct 2, 2026
Company news
Candel Therapeutics to Present at the SITC 2026 Annual Meeting
NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage…
Oct 1, 2026
Press release
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage…
Oct 1, 2026
FDA
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI
NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage…
Sep 30, 2026
Press release
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage…

SecBot reports

11 filings · 10 press releases · 1 bullish · 0 bearish · 10 neutral
All CADL filing & press-release reports (21)